Cargando…

MBCL-33. RARE PULMONARY TOXICITY IN THREE MEDULLOBLASTOMA PATIENTS UNDERGOING ANTIANGIOGENIC METRONOMIC COMBINATION THERAPY

BACKGROUND: Metronomic and targeted anti-angiogenesis therapy (MEMMAT) has emerged as a promising treatment for recurrent/progressive medulloblastoma. This treatment includes bevacizumab, oral agents (thalidomide, celecoxib, fenofibrate, etoposide & cyclophosphamide) and intrathecal chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lenzen, Alicia, Gryzlo, Daniel, McKenzie, Irene, Goldman, Stewart, Pillay-Smiley, Natasha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Medulloblastoma (Clinical)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715802/ http://dx.doi.org/10.1093/neuonc/noaa222.509

Ejemplares similares

MBCL-43. RECURRENT MEDULLOBLASTOMA – LONG-TERM SURVIVAL WITH A “MEMMAT” BASED ANTIANGIOGENIC APPROACH
por: Slavc, Irene, et al.
Publicado: (2020)

MBCL-41. LYMPHOHEMATOPOIETIC TOXICITY IDENTIFIED IN PATIENTS WITH MEDULLOBLASTOMA RECEIVING CRANIOSPINAL IRRADIATION
por: Watanabe, Atsuko, et al.
Publicado: (2020)

MBCL-52. ENDOCRINE PROFILE AFTER MEDULLOBLASTOMA TREATMENT
por: Pavon-Mengual, Miriam, et al.
Publicado: (2020)

MBCL-27. ASSOCIATION OF MEDULLOBLASTOMA WITH CHARCOT-MARIE-TOOTH DISEASE
por: Watanabe, Kenichiro, et al.
Publicado: (2020)

MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA
por: Robinson, Giles W, et al.
Publicado: (2020)

MBCL-35. SALVAGE RADIATION THERAPY FOR PROGRESSIVE AND/OR RELAPSED PEDIATRIC MEDULLOBLASTOMA
por: Baig, Muhammad, et al.
Publicado: (2020)

MBCL-48. OUTCOMES OF TREATMENT BASED ON THE ST. JUDE MEDULLOBLASTOMA-96 REGIMEN FOR JAPANESE CHILDREN WITH MEDULLOBLASTOMA
por: Fujimura, Junya, et al.
Publicado: (2020)

MBCL-08. INTEGRATIVE MOLECULAR ANALYSIS OF PATIENT-MATCHED DIAGNOSTIC AND RELAPSED MEDULLOBLASTOMAS
por: Kumar, Rahul, et al.
Publicado: (2020)

MBCL-30. NOVEL SMO MUTATION IN DESMOPLASTIC/NODULAR MEDULLOBLASTOMA: A CASE REPORT
por: Wright, Avery, et al.
Publicado: (2020)

MBCL-31. TREATMENT RESULTS AMONG 106 PATIENTS WITH MEDULLOBLASTOMA OF MOLECULAR SUBGROUP 3
por: Zheludkova, Olga, et al.
Publicado: (2020)

MBCL-02. ROLE OF PREOPERATIVE CHEMOTHERAPY IN METASTATIC MEDULLOBLASTOMA: A COMPARATIVE STUDY IN 92 CHILDREN
por: Guerrini-Rousseau, Léa, et al.
Publicado: (2020)

MBCL-32. HIGH-DOSE CHEMOTHERAPY WITH STEM CELL RESCUE FOR RECURRENT PREVIOUSLY IRRADIATED MEDULLOBLASTOMA
por: Salnikova, Ekaterina, et al.
Publicado: (2020)

MBCL-50. DISMAL OUTCOME OF HIGH RISK MEDULLOBLASTOMA TREATED WITH CHEMOTHERAPY FIRST APPROACH IN MALAYSIA
por: Quah, Shiao Wei, et al.
Publicado: (2020)

MEDB-33. The landscape of ecDNA in medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022)

MBCL-12. MOLECULAR SIGNATURES AND TUMOR INFILTRATING IMMUNOLOGICAL CELLS ASSOCIATED WITH ASIAN MEDULLOBLASTOMA PATIENT SURVIVAL
por: Liang, Kung-Hao, et al.
Publicado: (2020)

MBCL-10. LOCAL RECURRENCE AND SURVIVAL OUTCOMES OF MEDULLOBLASTOMA (MB) IN ADOLESCENT AND YOUNG ADULT PATIENTS (AYA)
por: Rongthong, Warissara, et al.
Publicado: (2020)

MBCL-24. CAN YOUNG CHILDREN WITH RELAPSED MEDULLOBLASTOMA BE SALVAGED AFTER INITIAL IRRADIATION-SPARING APPROACHES?
por: Erker, Craig, et al.
Publicado: (2020)

MBCL-18. ANALYSIS OF DNA METHYLATION PROFILES OF PEDIATRIC MEDULLOBLASTOMAS: EXPERIENCE AT THE BAMBINO GESÙ CHILDREN’S HOSPITAL
por: Miele, Evelina, et al.
Publicado: (2020)

MBCL-17. METASTATIC MEDULLOBLASTOMA CAN BE CURED WITHOUT EXCISION OF THE PRIMARY TUMOR: A SINGLE CENTER EXPERIENCE
por: Dvir, Rina, et al.
Publicado: (2020)

MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY
por: Chintagumpala, Murali, et al.
Publicado: (2020)

MBCL-14. A STUDY OF LOW-DOSE CRANIOSPINAL RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AVERAGE-RISK MEDULLOBLASTOMA
por: Mochizuki, Aaron, et al.
Publicado: (2020)

MBCL-04. 5 – AZACYTIDINE IN TREATMENT OF CHILDREN WITH DE NOVO AND RELAPSED METASTATIC MEDULLOBLASTOMA: RESULTS OF INTERCENTER PILOT STUDY
por: Levashov, Andrey, et al.
Publicado: (2020)

MBCL-22. EFFICACY OF DOUBLE-CONDITIONING REGIMEN COMPRISING THIOTEPA AND MELPHALAN FOR RELAPSED MEDULLOBLASTOMA – A SINGLE INSTITUTION EXPERIENCE
por: Yamasaki, Kai, et al.
Publicado: (2020)

MBCL-03. RESULTS OF HIGH-DOSE THIOTEPA, CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA
por: Gevorgian, Asmik, et al.
Publicado: (2020)

MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT
por: Mynarek, Martin, et al.
Publicado: (2020)

MBCL-05. TREATMENT OF CHILDREN WITH MEDULLOBLASTOMA WITHOUT METASTATIC INVOLVEMENT IN THE AGE GROUP OLDER THAN 3 YEARS: RESULTS OF INTERCENTER TRIAL
por: Levashov, Andrey, et al.
Publicado: (2020)

MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?
por: Obrecht, Denise, et al.
Publicado: (2020)

MBCL-01. METHYLATION PROFILING OF PEDIATRIC MEDULLOBLASTOMA IN SAUDI ARABIA IN A CLINICAL SETTING PERMITS SUB-CLASSIFICATION AND REVEALS NEW OUTCOME PREDICTIONS
por: Alharbi, Musa, et al.
Publicado: (2020)

MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES
por: Cohen, Kenneth, et al.
Publicado: (2020)

MBCL-28. LONG-TERM FOLLOW-UP RESULTS OF REDUCED DOSE CRANIOSPINAL RADIOTHERAPY AND TANDEM HIGH-DOSE CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK MEDULLOBLASTOMA
por: Lee, Ji Won, et al.
Publicado: (2020)

MBCL-13. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON “HEAD START” 4 CLINICAL TRIAL
por: Dhall, Girish, et al.
Publicado: (2020)

MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIAL
por: Dietzsch, Stefan, et al.
Publicado: (2020)

MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS
por: Mynarek, Martin, et al.
Publicado: (2020)

MEDB-32. Reducing treatment-related toxicity for children with WNT-activated medulloblastoma
por: Taylor, Jessica, et al.
Publicado: (2022)

MBCL-34. EFFICACY OF METHOTREXATE (MTX) ACCORDING TO MOLECULAR SUB-TYPE IN YOUNG CHILDREN WITH MEDULLOBLASTOMA (MB): A REPORT FROM CHILDREN’S ONCOLOGY GROUP PHASE III TRIAL ACNS0334
por: Mazewski, Claire, et al.
Publicado: (2020)

MBCL-23. PRELIMINARY ANALYSIS OF TREATMENT-RELATED TOXICITIES DURING INDUCTION CHEMOTHERAPY FOR PATIENTS ON THE HEAD START 4 TRIAL
por: Agarwal, Vibhuti, et al.
Publicado: (2020)

MBCL-15. IMPACT OF MOLECULAR SUBGROUPS ON OUTCOMES FOLLOWING RADIATION TREATMENT RANDOMIZATIONS FOR AVERAGE RISK MEDULLOBLASTOMA: A PLANNED ANALYSIS OF CHILDREN’S ONCOLOGY GROUP (COG) ACNS0331
por: Michalski, Jeff, et al.
Publicado: (2020)

MBCL-29. PHASE I/II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMA
por: Dufour, Christelle, et al.
Publicado: (2020)

MBCL-20. DETECTION OF SOMATIC MUTATIONS BY USING RNA-SEQ DATA IN CHILDHOOD MEDULLOBLASTOMA AND ITS POTENTIAL CLINICAL APPLICATION: A COHORT SERIES OF 52 CASES STUDY IN TAIWAN
por: Wong, Tai-Tong, et al.
Publicado: (2020)

MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP
por: Leary, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_anvjfbngibsv7b13qg64ab9nlo